What routine labs do you order for a patient with Rheumatoid Arthritis (RA) on Actemra (Tocilizumab)?

Routine Laboratory Monitoring for Rheumatoid Arthritis Patients on Actemra (Tocilizumab)

For patients with rheumatoid arthritis on tocilizumab (Actemra), monitor CBC and liver function tests within the first 1-2 months of starting therapy, then every 3-4 months thereafter, along with lipid profiles every 6 months. 1, 2, 3

Initial Monitoring (First 1-2 Months)

The following labs should be obtained within the first 1-2 months after initiating tocilizumab:

• Complete Blood Count (CBC) with differential to monitor for neutropenia and thrombocytopenia 1, 2, 3
• Liver transaminases (ALT/AST) to detect hepatotoxicity 1, 2, 3
• Lipid profile (total cholesterol, LDL, HDL, triglycerides) as tocilizumab can elevate lipid levels 1, 2, 3

Ongoing Monitoring (Every 3-4 Months)

After the initial monitoring period, continue the following tests every 3-4 months:

• CBC with differential 1, 2
• Liver function tests (ALT/AST) 1, 2

Lipid Monitoring (Every 6 Months)

• Lipid panel should be repeated every 6 months per FDA package insert recommendations 1, 3

Disease Activity Monitoring (Each Visit)

• C-reactive protein (CRP) is preferred over ESR as it is more reliable and not age-dependent 2, 4
• CRP should be repeated at each visit to monitor disease activity and guide treatment decisions 2

Dose Modifications Based on Laboratory Abnormalities

The FDA label provides specific thresholds for dose adjustments or discontinuation 3:

Liver Enzyme Elevations:

• ALT/AST >1-3× ULN: Reduce IV dose to 4 mg/kg or hold; for subcutaneous, reduce to every other week or hold 3
• ALT/AST >3-5× ULN (confirmed): Hold dosing until <3× ULN, then resume with dose reduction 3
• ALT/AST >5× ULN: Discontinue tocilizumab permanently 3

Neutropenia:

• ANC 500-1000 cells/mm³: Hold dosing; resume when ANC >1000 with dose reduction 3
• ANC <500 cells/mm³: Discontinue tocilizumab permanently 3

Thrombocytopenia:

• Platelets 50,000-100,000 cells/mm³: Hold dosing; resume when platelets >100,000 with dose reduction 3
• Platelets <50,000 cells/mm³: Discontinue tocilizumab permanently 3

Pre-Treatment Screening (One-Time)

Before initiating tocilizumab, the following screening tests are required:

• Tuberculosis screening with tuberculin skin test or interferon-gamma release assay (IGRA preferred if prior BCG vaccination) 2, 5
• Hepatitis B panel (surface antigen, surface antibody, core antibody) 2, 5
• Hepatitis C antibody 2, 5
• Baseline CBC, comprehensive metabolic panel, and lipid profile 2, 5

Important Clinical Considerations

Patients with comorbidities, abnormal baseline labs, or on multiple therapies may require more frequent monitoring than these standard intervals. 2 The American College of Rheumatology guidelines for juvenile idiopathic arthritis (which inform adult RA monitoring) conditionally recommend this monitoring schedule with very low certainty of evidence, but it aligns with FDA package insert recommendations 1.

Do not delay monitoring or dismiss laboratory abnormalities. Tocilizumab carries risks of serious infections, hepatotoxicity, cytopenias, and lipid elevations that require vigilant surveillance 3, 6. The FDA mandates specific dose modifications or discontinuation based on laboratory thresholds to prevent serious adverse events 3.

Annual tuberculosis testing is required for patients living, traveling, or working where TB exposure is likely. 2 This is critical given the immunosuppressive effects of biologic therapy.